Phase I trial of oral 5-fluoro-2′-deoxycytidine with oral tetrahydrouridine in patients with advanced solid tumors

被引：0
|
作者：
Coyne, G. O'Sullivan [1 ]
Chen, A. P. [1 ]
Kummar, S. [1 ]
Meehan, R. S. [1 ]
Collins, J. [1 ]
Zlott, J. [1 ]
Kelly, K. [2 ]
Lenz, H. J. [3 ]
Newman, E. M. [4 ]
Morgan, R. [4 ]
Juwara, L. [5 ]
Eiseman, J. [6 ]
Beumer, J. H. [6 ]
Tomaszewski, J. [1 ]
Doroshow, J. [1 ]
机构：
[1] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA
[2] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA
[3] USC, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[4] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
[5] Frederick Natl Lab, DCTD, Frederick, MD USA
[6] Univ Pittsburgh, UPMC, Inst Canc, Pittsburgh, PA 15260 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
269
引用
收藏
页码：S90 / S90
页数：1
相关论文
共 50 条
  • [1] Stability of 5-Fluoro-2′-deoxycytidine and Tetrahydrouridine in Combination
    Duoli Guo
    Paul B. Myrdal
    Kelly L. Karlage
    Sean P. O’Connell
    Travis J. Wissinger
    S. Esmail Tabibi
    Samuel H. Yalkowsky
    [J]. AAPS PharmSciTech, 2010, 11 : 247 - 252
  • [2] Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors
    Morfouace, Marie
    Nimmervoll, Birgit
    Boulos, Nidal
    Patel, Yogesh T.
    Shelat, Anang
    Freeman, Burgess B., III
    Robinson, Giles W.
    Wright, Karen
    Gajjar, Amar
    Stewart, Clinton F.
    Gilbertson, Richard J.
    Roussel, Martine F.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2016, 126 (02) : 225 - 234
  • [3] Stability of 5-Fluoro-2′-deoxycytidine and Tetrahydrouridine in Combination
    Guo, Duoli
    Myrdal, Paul B.
    Karlage, Kelly L.
    O'Connell, Sean P.
    Wissinger, Travis J.
    Tabibi, S. Esmail
    Yalkowsky, Samuel H.
    [J]. AAPS PHARMSCITECH, 2010, 11 (01): : 247 - 252
  • [4] Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors
    Marie Morfouace
    Birgit Nimmervoll
    Nidal Boulos
    Yogesh T. Patel
    Anang Shelat
    Burgess B. Freeman
    Giles W. Robinson
    Karen Wright
    Amar Gajjar
    Clinton F. Stewart
    Richard J. Gilbertson
    Martine F. Roussel
    [J]. Journal of Neuro-Oncology, 2016, 126 : 225 - 234
  • [5] A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine
    Newman, Edward M.
    Morgan, Robert J.
    Kummar, Shivaani
    Beumer, Jan H.
    Blanchard, M. Suzette
    Ruel, Christopher
    El-Khoueiry, Anthony B.
    Carroll, Mary I.
    Hou, Jessie M.
    Li, Chun
    Lenz, Heinz J.
    Eiseman, Julie L.
    Doroshow, James H.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 537 - 546
  • [6] A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine
    Edward M. Newman
    Robert J. Morgan
    Shivaani Kummar
    Jan H. Beumer
    M. Suzette Blanchard
    Christopher Ruel
    Anthony B. El-Khoueiry
    Mary I. Carroll
    Jessie M. Hou
    Chun Li
    Heinz J. Lenz
    Julie L. Eiseman
    James H. Doroshow
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 75 : 537 - 546
  • [7] Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors
    Geraldine O.’Sullivan Coyne
    Lihua Wang
    Jennifer Zlott
    Lamin Juwara
    Joseph M. Covey
    Jan H. Beumer
    Mihaela C. Cristea
    Edward M. Newman
    Stephen Koehler
    Jorge J. Nieva
    Agustin A. Garcia
    David R. Gandara
    Brandon Miller
    Sonny Khin
    Sarah B. Miller
    Seth M. Steinberg
    Larry Rubinstein
    Ralph E. Parchment
    Robert J. Kinders
    Richard L. Piekarz
    Shivaani Kummar
    Alice P. Chen
    James H. Doroshow
    [J]. Cancer Chemotherapy and Pharmacology, 2020, 85 : 979 - 993
  • [8] Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors
    Coyne, Geraldine O. 'Sullivan
    Wang, Lihua
    Zlott, Jennifer
    Juwara, Lamin
    Covey, Joseph M.
    Beumer, Jan H.
    Cristea, Mihaela C.
    Newman, Edward M.
    Koehler, Stephen
    Nieva, Jorge J.
    Garcia, Agustin A.
    Gandara, David R.
    Miller, Brandon
    Khin, Sonny
    Miller, Sarah B.
    Steinberg, Seth M.
    Rubinstein, Larry
    Parchment, Ralph E.
    Kinders, Robert J.
    Piekarz, Richard L.
    Kummar, Shivaani
    Chen, Alice P.
    Doroshow, James H.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (05) : 979 - 993
  • [9] Oral and intravenous pharmacokinetics of 5-fluoro-2′-deoxycytidine and THU in cynomolgus monkeys and humans
    Holleran, Julianne L.
    Beumer, Jan H.
    McCormick, David L.
    Johnson, William D.
    Newman, Edward M.
    Doroshow, James H.
    Kummar, Shivaani
    Covey, Joseph M.
    Davis, Myrtle
    Eiseman, Julie L.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 803 - 811
  • [10] Oral and intravenous pharmacokinetics of 5-fluoro-2′-deoxycytidine and THU in cynomolgus monkeys and humans
    Julianne L. Holleran
    Jan H. Beumer
    David L. McCormick
    William D. Johnson
    Edward M. Newman
    James H. Doroshow
    Shivaani Kummar
    Joseph M. Covey
    Myrtle Davis
    Julie L. Eiseman
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 76 : 803 - 811
12345